The concept of gene therapy follows logically from the observation that certain diseases are caused by the inheritance of a single functionally defective gene. Theoretically then, diseases caused by a known monogenic defect, such as adenosine deaminase deficiency or Gaucher's disease (also called glucosylceramide lipidosis) could be treated and potentially cured by the insertion and expression of a normal copy of the mutant or deleted gene in host cells. This idea of gene-replacement therapy represents the basic framework for the therapeutic approach to monogenic diseases. If a renewable population of cells (e.g., bone marrow stem cells) could be transduced with normal copies of the target gene, only a single or limited number of treatments would be necessary. Otherwise, the gene would need to be repeatedly administered to the patient over his or her life span. The recent identification of bone marrow stem cell populations and the ability to efficiently transduce other long-lived hematopoietic cells has made this approach feasible enough for testing in clinical trials (1, 2) . Recent reviews (3-7) have summarized progress in gene therapy.
The evolution of gene therapy has taken a somewhat unexpected course on the basis of these rather conceptually simple beginnings. Most of the approved protocols for what is now called gene therapy involve cancer patients. This would not have been anticipated because cancer seems to be a particularly unsuitable target for the classical approach of gene-replacement therapy. Cancer generally arises as the culmination of a multistep process that involves a variety of somatic gene alterations. At first blush, it might appear necessary to be able to correct all of the genetic abnormalities in the cancer cell, which is daunting since all of these are not known. It would also seem necessary to restore normal gene function to every cancer cell, which is beyond the capabilities of the vectors currently available for use in gene therapy. As it turns out, these considerations may not limit strategies involving gene replacement for therapy of cancer (more on this below). For these reasons, cancer gene therapy has focused instead on using recombinant DNA constructs to augment existing therapies. The treatment strategies that have evolved include the use of recombinant vaccines as immunotherapeutics, the protection of bone marrow during chemotherapy by transducing a drug-resistance gene into marrow stem cells, and the use of expression vector constructs that bring about the conversion of inactive prodrugs into active drugs. Some individuals may contend that these interventions do not constitute gene therapy but that they are instead recombinant DNA therapeutics that do nothing to restore normal functioning genes to the cancer cell. There is some merit in this distinction, since in some instances, the genes being introduced into the cells have no direct therapeutic function. Certainly, in situations where the introduced DNA is for diagnosis or prevention, the term therapy should not be used (8) . On the basis of this classification, many of the interventions to date in cancer would be classified as gene therapeutics as distinct from gene-replacement therapy.
Current Approaches to Gene Therapeutics and Gene Therapy Immunotherapy Using Recombinant DNA Constructs Expressing Cytokines and Lymphokines
An immune response against syngeneic tumors can be generated in animal models using a variety of tumors induced by chemical carcinogens and viruses. Tumor regression can result from manipulating the human immune response with interleukin 2 (IL-2). The response rates of cancer patients to these immune manipulations is low and primarily confined to patients with melanoma and renal cell cancer. In addition, cytokines secreted by tumor cells into which cytokine gene-expressing recombinant DNA constructs have been inserted have elicited antitumor immune responses in preclinical (i.e., animal model) studies (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . This suggests that the results of immunotherapy could be improved by the use of recombinant DNA tumor cell vaccines or by adoptive transfer of genetically engineered lymphocytes. A major advantage of this approach is the potential to generate a systemic immune response against the tumor.
Current protocols based on this idea use tumor-infiltrating lymphocytes (TILs), tumor cells, or fibroblasts to express cytokine genes. Initially, it was felt that TILs had a propensity to traffic specifically to tumor cells and, therefore, that expression of cytokines by TILs might avoid the toxicity associated with systemically administered cytokines. Thus, the expression of cytokine genes, such as tumor necrosis factor (TNF), by adoptively transferred gene-transduced TILs could possibly be concentrated at the tumor site. Subsequently, however, this was disproved by a study that showed that tumors did not selectively take up or retain TILs marked with the neo r gene (20) . Another approach is to use autologous tumor cells transduced with a cytokine gene as a vaccine (9, (11) (12) (13) 15) . In many instances, however, tumor cells will not be available from patients, and even if available, the transduced cells may not express the cytokines. An alternative approach is to inject fibroblasts that have been engineered to express the cytokine gene. However, this approach also has its disadvantages: In one study, antitumor immunity was not induced by IL-2-expressing mammary stromal fibroblasts (16) .
Yet another approach is to make tumor cells more immunogenic. T cells recognize protein antigens after they are degraded into peptides that bind to histocompatibility complex molecules and are then transported to the tumor cell surface. Tumor cells, however, may be defective in their expression of class I or class II histocompatibility molecules, thus leading to defects in antigen presentation. Additional costimulatory molecules, such as B7-1 and B7-2, may be needed for effective induction of the efferent arm of the immune response to tumor antigens, but tumor cells may be defective in the expression of such molecules (21) . If so, then restoration of costimulatory gene expression might enhance tumor cell immunogenicity (22) . One substantial difficulty with this approach is the heterogeneity and unpredictability of loss of costimulatory molecules in human cancers. For example, one study of prostate cancer showed that cells vary in their loss of histocompatibility and transporter molecules (21) . This approach may therefore require replacement of multiple genes within the tumor cell to elicit an effective immune response. It is also possible that, despite activation of the efferent arm of the immune response to tumor antigens, ineffective transport mechanisms may result in an antigen density too low to be recognized by the cytotoxic effector cells.
Another immunologic approach involves the use of vectors that express tumor-rejection antigens. Recently, immunodominant epitopes on human melanoma cells have been identified that are recognized by TILs and are associated with tumor regression (23) . However, as with the other approaches, there are potential difficulties. The immune response to an immunogen is clonal, but in tumors, antigen expression is heterogeneous (24) . Tumors also produce factors that suppress the immune response (25) . Moreover, as discussed above, cancer cells possess a variety of defects in the machinery of antigen presentation. Thus, it is not clear that an immune response elicited by cells possessing the appropriate genes for antigen presentation will elicit an immune response effective against cells expressing the antigen but defective in components of antigen presentation. The identification of tumor rejection antigens from a variety of cancers and of the critical components of afferent and efferent limbs of the immune response that are defective in cancer patients are important topics for future studies.
A survey was conducted of principal investigators for cancer gene therapy protocols to obtain current information on protocols completed or in progress. Protocols were identified from existing comprehensive listings (26) (27) (28) (29) . Principal investigators personally communicated the results of their studies with full knowledge that the results would be summarized in this review. Following completion of the survey, the results were resubmitted to the principal investigators for verification of accuracy. The results were tabulated as of June 19, 1996 (Appendix Table  1 ). Published clinical trial reports are cited.
Sixty protocols worldwide had been designed to augment the immune response against cancers by gene therapy (i.e., by vaccine or direct cytokine or costimulatory molecule gene transduction) (Appendix Table 1 ). A total of 376 patients have been entered in these ongoing protocols. Major tumor regressions (defined as either complete responses or partial responses) have been observed in 15 of 237 patients with sufficient information to evaluate responses.
Drug-Sensitivity Genes
Selective transduction of tumor cells with a gene whose product can convert a relatively nontoxic prodrug administered systemically to a toxic metabolite in the cancer cell was one of the first strategies proposed for the use of recombinant DNA constructs in cancer patients. In the first protocol to be approved using this strategy, brain tumors are transfected with a retroviral vector expressing the herpes simplex virus thymidine kinase (HSV-TK) gene. Systemic gancyclovir that enters the tumor cell is metabolized to cytotoxic gancyclovir triphosphates by cells expressing HSV-TK (30) . A potential advantage of this technique is selective uptake of the vector and expression by proliferating cells, presumably the tumor cells. Studies (31) (32) (33) in a rat glioma model showed that marked tumor regression occurred when only a small fraction of tumor cells were transfected with the retroviral HSV-TK. This cytotoxic effect of transduced on nontransduced cells has been termed the ''bystander effect.'' There are several mechanisms that appear to mediate bystander effects and these may act concurrently. They include transfer of toxic metabolic products of gancyclovir through gap junctions, phagocytosis of apoptotic vesicles of dead tumor cells by live tumor cells that mediate apoptosis, and induction of an immune response against the tumor. Retrovirus-and adenovirusmediated transfer of the cytosine deaminase gene, which confers cellular sensitivity to 5-fluorocytosine, to tumor cells has been reported (34, 35) .
As of June 1996, 21 protocols using this strategy had been proposed (Appendix Table 1 ). A total of 104 patients have been entered in these ongoing protocols. Major tumor regressions have been observed in eight of 62 patients, with sufficient information to evaluate responses.
Drug-Resistance Genes
The transfer of genes into normal cells to augment existing cancer treatments is also under investigation. Current protocols are attempting to enhance marrow protection during chemotherapy by transducing the multiple-drug resistance gene (MDR1) into normal bone marrow or blood-derived stem cells (36, 37) . The MDR1 gene produces P-glycoprotein, which functions as a cellular efflux pump and may be responsible for the resistance of some tumor cells to various hydrophobic cytotoxic drugs. Insertion of the MDR1 gene into normal marrow stem cells produces a population of cells that can be selected for resistance to a systemically administered chemotherapeutic agent (38, 39) . A potential advantage of this approach is that it may permit higher doses of chemotherapy to be given with less toxicity and more efficacy. Retrovirus-mediated expression of the DNA repair protein O-methylguanidine-DNA-methyltransferase protected mouse primary hematopoietic cells from nitrosourea-induced toxicity, and marrow from transgenic mice expressing methotrexate-resistant dihydrofolate reductase was protective against methotrexate toxicity in recipient syngeneic mice (40) (41) (42) .
Approved protocols for MDR1 include protocols for the treatment of patients with breast or ovarian cancer who are receiving paclitaxel (Taxol). There are, however, some potential problems with this strategy: higher doses of chemotherapy may not translate into higher response rates, nonhematologic toxic effects may be dose limiting, and cancer cells in the marrow may be transduced with the drug-resistance gene. As of June 1996, eight protocols using this strategy had been proposed and are being tested in clinical trials (Appendix Table 1 ). Insufficient information is available, however, to evaluate the therapeutic efficacy.
Tumor Suppressor Gene Replacement and Oncogene Inactivation
The identification of specific genes that contribute to the development of cancer presents an opportunity to use these genes and their products as prevention and treatment targets. The genes that are implicated in carcinogenesis include dominant oncogenes and tumor suppressor genes (43, 44) . Protooncogenes (normal homologues of oncogenes) participate in critical cell functions, including signal transduction and transcription, but only a single mutant allele is required for the malignant transformation of a cell. Primary modifications in the dominant oncogenes that confer gain of transforming function include point mutations, amplifications, translocations, and rearrangements. Tumor suppressor genes, which regulate gene transcription and cell proliferation, undergo homozygous loss of function, either by mutation, deletion, or a combination of these. It is possible that modification of the expression of dominant and tumor suppressor oncogenes may influence certain characteristics of cells that contribute to the malignant phenotype. Thus, gene replacement could mediate induction of tumor cell death by direct killing (e.g., apoptosis) or a bystander effect, induction of tumor cell dormancy, or prevention of malignant progression of premalignant cells.
Oncogenes. The ras family of oncogenes is among the most common activated oncogenes found in human cancer and is therefore a potential target for oncogene-inactivation strategies. The ras (i.e., H-ras, N-ras, and K-ras) genes each encode an oncoprotein that is located on the inner surface of the plasma membrane, that has guanosine triphosphatase (GTPase) activity, and that may participate in signal transduction. These genes are activated by point nucleotide mutations that alter the amino acid sequence of their protein product, p21 (45) . Antisense technology involving introduction into the cell of a gene construct that has a base sequence complementary to the RNA sequence targeted for inhibition has been used to study the effects of eliminating expression of a mutant K-ras oncogene in human lung cancer cells (46) . The antisense and sense sequences bind by Watson-Crick base pairing. Protein synthesis may be inhibited at the level of messenger RNA (mRNA) splicing, transport, or translation (47) . Transduction with either an antisense K-ras complementary DNA (cDNA) plasmid or retroviral construct selectively blocked the production of mutant K-ras mRNA and reduced the growth rate of human lung cancers in vitro and in vivo in nu/nu mice (46, 48, 49) . Alternative methods of reducing or blocking the expression of oncogenes involve the use of antisense oligonucleotides (that bring about the degradation of oncogene-encoding mRNA), ribozymes (that directly cleave oncogene mRNA), and intracellular single-chain antibodies (50) (51) (52) (53) (54) (55) .
Tumor suppressor genes. The inactivation of certain genes may contribute to tumor growth. In one scenario, both copies of the gene must be eliminated or inactivated to eradicate the growth-suppressive function of the gene (43, 56, 57) . Theoretically then, replacement of a functioning copy of the tumor suppressor gene in cells with homozygous loss of function could restore normal growth and proliferation pathways. Mutations in the p53 (also called TP53) gene are common in a wide spectrum of tumors (57) . The p53 gene encodes a 393-amino acid phosphoprotein that can form complexes with viral proteins, such as large-T antigen and E1B, both of which functionally inactivate the p53 protein. Missense mutations that occur in the p53 gene are essential for its transforming ability. The p53 protein also appears to be multifunctional because it has major domains that interact with other proteins, that allow p53 oligomers to form, that bind DNA in a sequence-specific manner, and that transactivate the expression of certain genes. Thus, abnormalities in one or more of these functions could contribute to abrogation of the tumor suppressor function of p53 (58) . Since the wild-type p53 (wt-p53) protein may either suppress the expression of genes that contribute to uncontrolled cell growth and proliferation or activate genes that suppress uncontrolled cell growth, the absence or inactivation of wt-p53 may contribute to transformation. The restoration of wt-p53 expression in cells with mutant or deleted p53 is sufficient to cause apoptosis or growth arrest, despite multiple genetic abnormalities present in the cell (59, 60) .
Restoration of wt-p53 gene expression using a retroviral p53 expression vector suppressed growth in H358a (deleted p53) and H322a (mutated p53) human lung cancer cell lines but had no effect in another transduced human lung cancer cell line, H460a, which has an endogenous wild-type p53 gene (61) . In mixing experiments, retroviral wt-p53-transduced cells could reduce the growth rate of nontransduced cells in human lung cancer, indicating a bystander effect. In another study (62) , the direct administration of a retroviral wt-p53 expression vector (LNp53B) in an orthotopic human lung cancer model led to the suppression of tumor growth.
An adenovirus expression vector was also developed for delivery of wild-type human p53 cDNA (Ad-p53) to cells. This p53-expression vector induced apoptosis in cancer cells with mutated or deleted p53 but only minimally affected growth of cells containing wt-p53 (63) . The vector inhibited tumorigenicity in the mouse model of orthotopic human lung cancer (49) . Moreover, similar p53-adenovirus vector constructs can inhibit growth of rat gliomas, human head and neck cancers, and human colon cancers in nu/nu mice and can mediate p53 gene expression in bladder and liver cancers (64) (65) (66) (67) (68) (69) (70) (71) . The products of other tumor suppressor genes, such as p16 and a truncated retinoblastoma gene (Rb), have been found to suppress tumor growth in animal models (72, 73) . The evaluation of gene therapy combinations involving use of tumor suppressor genes and constructs that inactivate oncogenes is an important area for future research.
The presence of a wt-p53 gene may be necessary for induction of apoptosis by some chemotherapeutic agents (74, 75) . One study (76) examined whether sequential administration of Adp53 and cisplatin (CDDP) could induce synergistic tumor regression in vivo. After 3 days of direct intratumoral injection of Ad-p53, p53-deleted human lung tumors grown as subcutaneous xenographs in nu/nu mice showed a modest slowing of growth; tumors injected with an adenovirus vector containing the p53 transgene regressed if CDDP was administered intraperitoneally for 3 days. CDDP alone had no effect on tumor growth in this model system. Moreover, in tumors treated directly with the combination, extensive areas of apoptosis were visualized by use of the terminal deoxynucleotidyl transferase biotin deoxyuridine triphosphate nick end-labeling method (that detects 3Ј-hydroxyl ends of DNA fragments). In contrast, tumors treated with either CDDP or Ad-p53 alone showed no apoptosis.
Clinical applications. The use of viral vectors to replace defective tumor suppressor genes or inactive oncogenes in tumors is thus supported by the following observations: 1) Viral gene transfer is more efficient in cancer cells than expected from studies of normal organ gene transfer (61, 77) ; 2) viral vectors spread readily through three-dimensional cancer cell matrices (78); 3) transduced cells mediate bystander killing of nontransduced cells (61); and 4) correction of a single genetic lesion is sufficient to mediate potentially clinically significant tumor regressions (61,77). There are limitations with this therapeutic approach. At present, the administration of viral vectors to patients is limited to delivery to local and regional tumors since current vectors are not approved for systemic administration. Immune responses to existing vectors may, however, limit repetitive administrations. Improvements in vector transduction efficiency are needed to increase the percentage of tumor cells that take up the vector.
As of June 1996, 13 protocols using this strategy had been proposed (Appendix Table 1 
Critical Areas for Future Development
Despite the proliferation of clinical protocols using gene therapy strategies, there are many aspects of gene transfer that are less than ideal. One of the most important areas for future research is vector design. The vector is critical for gene delivery and expression, but existing vectors have limitations ( Table 1 ). The remainder of this review will focus on specific topics related to vector development.
Viral Vectors
Retrovirus. The majority of approved gene-transfer protocols use retroviral vectors. For cancer applications, the propensity of the retrovirus to integrate into dividing cells appears to be an advantage. For ex vivo applications, the retrovirus has a sufficiently high transduction efficiency. To date, this has been the most useful vector for achieving stable integration of foreign DNA into the target cell. However, there are several potential limitations for retroviruses (5, 79) . First, their capacity is limited to about 8 kilobases (kb). Second, serum complement can inactivate retroviruses, although a recent study (80) showed that retroviruses produced by producer cells of human origin are resistant to complement inactivation. Third, the currently achievable titers (10 7 ) are low compared with what will be needed for the treatment of large tumors. Fourth, large-scale production is difficult, with the most substantial problem being the appearance of replication-competent retroviruses. This last problem has been reduced by using packaging cell lines that split the packaging signals between two plasmids (81) . Fifth, the host range of some retroviruses may be limited. However, the technique of pseudotyping may overcome this limitation because it involves the use of packaging cell lines in which envelop proteins having the desired host range are substituted for the endogenous retroviral protein (82, 83) . For example, amphotropic Moloney leukemia virus infects hepatocytes poorly; using a packaging cell line that provides a Sendai virus surface-F glycoprotein conferred infectivity to hepatocytes (84) .
Adenovirus. The limitations of recombinant retroviral vectors have led to the need for more versatile vectors for the successful application of gene therapy. Attention has focused on viral vectors based on the Ad5 since this double-stranded DNA virus is capable of high-level transduction of many cell types, regardless of the mitotic status of the cell (85) . First-generation recombinant adenoviruses have been generated by homologous recombination into the E1 or E3 regions of the viral genome, resulting in a dependence on the embryonic kidney cell line 293 as a helper cell that provides the E1 gene product in trans missing from the recombinant virus. The E1 region must be intact for viral replication so that the E1-deleted virus cannot replicate outside the packaging cell line. This vector can be produced at substantially higher viral titers (>10 11 ) than retrovirus with little manipulation (86) . Moreover, studies (85, 87) have now shown that minimal amounts of the virus can generate high-level transduction of cells with efficient levels of gene expression in most tissues except hematopoietic cells. So far, the application of recombinant adenoviral vectors to gene therapy has primarily been in the treatment of benign disorders, such as cystic fibrosis (88), but recently, the focus has broadened to encompass cancer applications (89) . Some protocols propose using this vector to deliver drug-sensitivity genes, such as the HSV-TK gene, to kill cancer cells in either the brain or the liver, while others propose using it to deliver the gene for the tumor suppressor p53 into lung, head and neck, or liver cancer cells after direct tumor injection.
Although adenovirus has shown much use in gene therapy, this vector is not without problems. The presence of intact viral genes in the recombinant virus have resulted in low levels of viral gene expression, which leads to cellular toxicity and cell death (90) . As a result, the length of gene expression is limited, and the virus may not be able to be administered to previously treated recipients because of an immune response to viral antigens. For example, specific lymphocyte-mediated cytotoxicity to E1a-deleted adenovirus-infected mouse hepatocytes has been observed (91) . Second-generation recombinant adenoviruses have been developed by taking advantage of temperaturesensitive mutations in the E2a gene to bring about minimal viral late gene expression, to blunt the host immune response against viral proteins, and to increase the duration of therapeutic gene expression (90, 92) . Another approach to this problem is to use an adenovirus deleted of all sequences except the internal terminal repeats and contiguous packaging sequences (93) . Humoral immune responses of the immunoglobulin A type have been reduced by the administration of IL-12, which inhibits the T H 2 subset of T-helper cells that are necessary for initiation of antibody production (94) . Other groups have used immunosuppressive agents, such as cyclosporin, to mediate a transient attenuation of the immune response in previously treated recipients, allowing for subsequent gene delivery and expression (95, 96) . And finally, since adenoviruses have 47 different serotypes, some investigators have proposed that distinct serotypes be sequentially administered to patients in an attempt to circumvent the neutralizing antibody response (97) . Adeno-associated virus, herpesvirus, poxvirus, vaccinia virus, and baculovirus. Work in the field of virology has also identified a large number of viruses that have unique characteristics useful for their application in gene therapy. Adenoassociated virus, a small, linear single-stranded DNA virus, can be generated in which most of the viral genome has been replaced with DNA encoding a potentially therapeutic gene. As a result, this virus has less chance of generating an immune response. A preliminary study (98) has shown that this virus is capable of infecting both dividing and nondividing cells as well as hematopoietic cells. This virus has also been applied in gene therapy protocols for cystic fibrosis. However, this vector also has its problems, which primarily result from the removal of the viral genome. The wild-type virus has the ability to integrate at a specific location in chromosome 19; however, this activity seems to be lost in the recombinant virus (99) . Also, the generation of recombinant virus results in low viral titers (10 4 ), partly because of the inefficient process of producing the virus. Production requires the use of a helper virus, such as adenovirus, to provide the missing viral genes, and, as a result, contamination of preparations with helper virus can frequently occur. The inability to develop a high-titer-producing packaging cell line continues to be a limiting factor for the efficient use of this system. The herpes simplex virus, a large, double-stranded DNA virus, has received attention because of its ability to establish latent infection in the brain. As a result, it has been used in some initial applications to deliver therapeutic genes to neurons and could potentially be used to deliver therapeutic genes to some forms of brain cancer (100). However, the characteristics of this virus have yet to be fully determined because of the large size of the genome (150 kb). Vaccinia viruses, poxviruses, and baculoviruses have also received recent attention for use in the delivery of genes for therapeutic purposes. Recombinant forms of the vaccinia virus can accommodate large inserts and are generated by homologous recombination. Thus far, this vector has been used to deliver ILs, such as human IL-1␤ and the costimulatory molecules B7-1 and B7-2, for either in vitro or ex vivo applications (101, 102) . Avipox virus vectors can infect and express recombinant proteins in human cells without viral replication, allowing this vector to be used for vaccination against disease (103) . Baculovirus, an insect virus system, has been used primarily for protein expression but is now being considered for applications in gene therapy because of its ability to express proteins at high levels (104) 
Nonviral Vectors and Naked DNA
One of the more promising areas of vector development has been that of nonviral vectors. These vectors are designed to deliver therapeutic genes to cells without the aid of an intact virus. This group of vectors primarily consists of liposomes, molecular conjugates, and naked DNA delivered by mechanical methods. Liposomes, when combined with DNA of any size, form a lipid-DNA complex that is capable of delivery to many cell types (105) . The wide range of lipid molecules available (most notably, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N- N-[1-(2,3-) dioleyloxy)propyl]-n,n,n-trimethylammonium-chloride [DOTMA]) and the ease with which the complexes can be generated have resulted in clinical protocols in which the use of liposomes (i.e., the technique of lipofection) for the delivery of therapeutic genes in cancer gene therapy has been proposed (91). However, this system lacks the ability to target to specific cell types and mediates gene transduction mainly at the site of administration. Other forms of lipids, such as glycolipids, can be used to target specific organs, such as the liver, but the presence of the lipid component in the complex can result in nonspecific uptake by the reticuloendothelial system, causing a loss of targeting specificity (108).
The emerging need for targeted gene delivery to a specific cell type has resulted in the development of molecular conjugates, which consist of protein or synthetic ligands to which a nucleic acid-or DNA-binding agent has been attached for the specific targeting of nucleic acids (i.e., plasmid DNA) to cells (109) (110) (111) . Once the DNA is coupled to the molecular conjugate, a protein-DNA complex results. This gene delivery system, originally developed by Wu and Wu (109) , has been shown to be capable of targeted delivery to many cell types through the use of different ligands (109) . This system can also deliver any type or size of nucleic acid and has resulted in highly specific and efficient gene delivery in vitro (112, 113) . Problems such as the need for a nonviral endosomal lysis agent and short duration of gene expression have limited its use in vivo (114) . However, this system does provide the basis for the generation of ''synthetic viruses'' capable of efficient gene delivery without the detrimental effects of intact viruses.
The simplest of delivery systems for gene therapy is the delivery of DNA without the use of a virus or synthetic vector. This has been accomplished by using mechanical methods of delivery, such as direct injection of DNA into tissue or by highvelocity bombardment of tissues with DNA attached to gold particles. The injection of naked DNA into muscle has led to DNA delivery and expression in vivo (115, 116) . Recently, this technology has been applied to cancer for the generation of cancer vaccines, and the related studies have resulted in at least three clinical protocols for the generation of antitumor immunity against colon cancer and melanoma (89) . However, this method of delivery is limited only to cells near the injection site acquiring the DNA, with no tissue targeting. The delivery of DNA by particle bombardment can generate gene expression in the liver and in tumors, but it also suffers from a lack of targeting, the
Vector Targeting and Specificity
One of the more important aspects of gene therapy continues to be the specificity of therapeutic gene expression. This is being addressed at several levels, namely, vector targeting, tissuespecific promoters, route of delivery, and modulation of immune receptors. Viral vectors, which normally cannot target specific cells, do have some specificity that results from tissue tropisms. Adenovirus, which normally infects the lung epithelium, can also mediate high-level transduction of the liver parenchyma (85) . Retroviral vectors have no specific tissue tropism; however, the genes delivered by such vectors are integrated and expressed only in dividing cells, owing to their ability to integrate into the host cell genome during DNA replication (117) . Also, the herpes simplex virus, which is capable of infecting many cell types, can efficiently infect and mediate prolonged expression in neuronal cells (100) .
Two research groups (118, 119) have shown that viral vectors can be targeted to specific cell types after attachment of ligands to the viral capsid either chemically or with antibodies. A third group (120) has shown that the retroviral envelope gene can be manipulated to express chimeric protein that consists of the envelope with a cell-specific ligand. This work is still evolving and potentially provides the capability of developing targeted retroviral vectors. It may also be possible to alter binding motifs of the adenovirus coat proteins to enhance specific binding (97) .
Nonviral vector targeting has been accomplished primarily through the use of molecular conjugates and protein/DNA complexes (107-109). Several ligands have been used for cellspecific gene delivery, such as the vitamin folate to promote delivery into cells that overexpress the folate receptor (e.g., ovarian carcinoma cells) (121) and the glycoprotein asialoorosomucoid (ASOR), which has been used to mediate specific uptake by the liver parenchyma. The malaria circumsporozoite protein has been used for the liver-specific delivery of genes under conditions in which ASOR receptor expression on hepatocytes is low, such as in cirrhosis, diabetes, and hepatocellular carcinoma (122) . Recently, the overexpression of receptors for epidermal growth factor (EGF) on cancer cells has allowed for specific uptake of EGF/DNA complexes by lung cancer cells (123) . Another approach involved use of the human papillomavirus (HPV) capsid to partially identify the HPV receptor by using the capsid as a ligand for the attachment and delivery of a reporter gene to cells (124) . Since the targeting of these complexes is done through a receptor that is internalized by receptormediated endocytosis, fusion of the endosome with the lysosome results in degradation of the DNA attached to the molecular conjugate (109) . Although agents have been identified that increase gene expression through endosomal lysis (i.e., adenovirus), a truly efficient nonviral endosomal lysis has yet to be identified.
The next level of specificity can be generated by using tissue or cell-specific promoters. The cytomegalovirus promoter and enhancer has been identified to be active primarily in rapidly dividing cells, since the enhancer is activated by transacting factors present in the nucleus (125) . Adding to this is the fact that this promoter is the strongest identified thus far and as a result, these characteristics have made it a good choice for use in cancer gene therapy (126) . The promoter for the carcinoembryonic antigen (CEA) gene has been incorporated in vectors and it has shown that cell-specific expression of the resulting CEAexpression vector constructs in tumors cells, such as those of pancreatic carcinoma, can be achieved (127) . The regulatory sequences of the human surfactant protein A gene have been used to generate cell-specific expression in non-small-cell lung cancers that express this protein (128) . Also, melanoma cellspecific expression of ␤-galactosidase has been generated by using as little as 769 base pairs of the 5Ј-flanking sequences of the tyrosinase gene (129) . A stress-inducible glucose-related protein (grp) promoter for grp78 that is responsive to hypoxic conditions has been shown to mediate high-level reporter gene expression in a mouse fibrosarcoma model (130) . Nevertheless, the identification of a truly universal cancer-specific promoter has been difficult because of the heterogeneity of cancer types.
The route of delivery can also aid in specificity. The direct injection into tumor of retroviral producer cells, e.g., by stereotactic administration to gliomas in the brain and bronchoscopic administration to lung tumor, allows for infection of cells in the area injected and has formed the basis for several clinical protocols (89) . Systemic, intravenous administration of vectors, while not providing tissue specificity, provides a simple means of administration (105, 106) . Peritumoral injection, which limits the administration to the neighboring tumor, and compartmental administration, such as intraperitoneal injection, have both shown efficacy in preclinical models (131, 132) . An alternative to these in vivo approaches is the ex vivo approach, which was the first approach used for gene therapy. In this approach, cells are removed from the patient, transfected by the delivery system, and then replaced into the patient. This procedure provides the greatest degree of specificity and is now being used to treat melanoma and hematologic disorders (133, 134) .
Cytotoxic lymphocytes or TILs could be targeted to tumors by the induction of specific immune receptors mediated by gene transfer. Already, the T-cell receptor recognizing the MART-1 melanoma antigen has been cloned and expressed in Jurkat cells (135) . The expression of T-cell receptors that recognize tumor antigens could then be used to redirect TILs or other cytotoxic lymphocytes to the tumor. Single-chain antibodies to a renal cell carcinoma antigen have also been expressed in anti-CD3-activated human peripheral blood lymphocytes and have been shown to lyse tumor cells specifically (136) .
Gene Integration and Duration of Expression
The length of therapeutic gene expression is an important determinant of the effectiveness of the therapy. Vectors such as retrovirus and possibly adeno-associated virus have the ability to integrate into the host genome, resulting in long-term expression that may also be associated with genotoxicity. As for cancer gene therapy, long-term expression may apply more to the expression of antisense genes. However, therapeutic genes, such as those for tumor suppressors or drug sensitivity, may only require short-term expression to kill cells. Short-term gene expression has been seen with adenoviral vectors, since the linear viral ge-nome remains episomal and therefore is susceptible to degradation (85, 137) . This also occurs with nonviral vectors, since the nucleic acid lacks maintenance sequences and becomes degraded. However, the nonviral systems, by virtue of their ability to provide the necessary signals, may provide the best potential for the further development of gene constructs that mediate episomal maintenance, replication, or integration into the host genome.
Regulation of Transcription: Inducible Promoters and Temperature-Sensitive Mutants
The control of gene expression at the transcriptional level may be the most difficult goal to achieve. The strengths of various promoters can be easily determined; however, more critical to expression may be the regulation of the promoter. Moreover, the heterogeneity of tumor types will make the generalization of regulation difficult. Thus, the ability to simply induce rather than regulate the expression of therapeutic genes may be much more practical at present. Early growth response gene-related promoter sequences that increase gene expression following exposure to radiation have been identified (138) . As a result, therapeutic gene expression induced by irradiation has been shown to result in cell-specific killing. Another way to control gene expression is to use temperature-sensitive mutants; for example, it has been shown that viral gene expression can be ablated with the use of temperature-sensitive mutant sequences in the viral genes (92) .
Interactions With Other Cancer Therapies
Surgery, radiation therapy, and chemotherapy are currently the primary methods for cancer treatment. Gene therapies may interact in synergistic or additive ways with them. For instance, Fujiwara et al. (76) have shown that replacing the p53 gene in p53-deficient cancer cell lines enhances the sensitivity of these cells to CDDP and results in greater tumor cell killing. Recently, Son and Huang (139) have shown that treating CDDP-resistant tumor cells with CDDP increases the sensitivity of these cells to transduction by DNA-carrying liposomes. Also, Chen et al. (140) have shown that HSV-TK and IL expression can be combined to mediate improved tumor killing. As a whole, these studies indicate that improved methods for treating cancer that combine conventional cancer treatments and gene therapy can be developed and applied for a greater therapeutic effect.
Vector Immunogenicity and Toxicity
To date, no major toxic effects associated with the use of retrovirus vectors for gene transfer in humans have been reported. Longer term toxic effects are theoretically possible, as discussed above, but these have not yet been observed. The use of adenovirus vectors, however, has highlighted two problems: immune responses to the vector that reduce transgene expression on subsequent administrations (discussed above) and toxic effects related to expression of viral proteins.
Toxic effects in a patient have been reported after administration of an adenovirus vector expressing the cystic fibrosis transmembrane conductance regulator (CFTR) gene into the right lower lobe bronchus (141). The patient developed headache, fatigue, fever, tachycardia, and hypotension, but the specific contributions of the expression of adenovirus proteins or the CFTR gene product to the observed syndrome is not known. Adenovirus proteins can mediate inflammatory responses in lung tissue that are abrogated to some extent by the presence of the adenovirus E3 protein, which reduces histocompatibility antigen expression (142) (143) (144) .
Also, minimal toxicity of an adenovirus vector expressing the wt-p53 gene has been reported in human bronchial epithelial cells and in a mouse model (145) . Growth of the human bronchial epithelial cells was not altered, and localized peribronchiolar and perivascular infiltrates were observed following intratracheal injection of 10 9 and 10 10 plaque-forming units. These problems can likely be overcome, however, by modifying vector structure to eliminate expression of endogenous viral genes, improving vector targeting, and using immunomodulators to reduce the immune response against the vector.
Summary and Conclusions
Conceptually, it is possible to extend the technique of gene therapy to cancer prevention, that is, to use it to halt the progression of premalignant lesions to invasive cancer. For example, premalignant lesions, such as bronchial dysplasia or Barrett's epithelium, have tumor suppressor gene mutations that may be amenable to gene therapy (146, 147) . In any case, preventing the development of invasive cancers is clearly preferable to treating them once established.
So far, the application of gene therapy agents in phase I trials has been limited to patients with advanced incurable cancer. However, once the safety and efficacy of these agents have been demonstrated, trials in patients with earlier stages of disease should be undertaken. Indeed, there is a potential role for these agents in the treatment of patients with limited invasive cancer. Since local recurrence or persistence of local disease is still a major problem for many cancers, such as those of the lung, head and neck, and pancreas, intralesional injections or adjuvant use of gene-based agents to prevent local recurrence after surgery could be considered. Sites of limited metastatic disease could also be injected with these agents percutaneously. Moreover, if these agents are efficacious, their lack of toxicity may provide a sufficiently high therapeutic index to allow their use as an adjuvant to surgery in patients with earlier stages of cancer or as a preventative for second primary cancers in individuals with genetic abnormalities in premalignant lesions. The high titers achievable with adenovirus vectors suggest that they could be used systemically, and vector targeting by expression of receptor ligands in the viral capsid is also possible. Aerosolized delivery to the respiratory epithelium of such agents encapsulated in liposomes has also been reported (148) .
Although the first clinical protocols in gene therapy began just 5 years ago, progress has been rapid, and important observations have emerged from ongoing clinical trials. In general, retroviral vectors appear to be safe vehicles for gene transfer. Neither short-nor long-term toxicity has yet been associated with these vectors. Gene transfer and expression into cancer cells in vivo are possible, both with viral and nonviral vectors. Tumor regression has been observed by several investigators for immunotherapy/cytokine, drug sensitivity, and tumor suppressor/antisense protocols. Despite these successes, however, inter-preting response rates in phase I trials is difficult. Taken at face value, these response rates appear comparable to those achieved with many single-agent chemotherapy protocols in comparable advanced-stage patients. Yet, most cancer gene therapy protocols have used vectors to augment existing therapeutic approaches, such as immunotherapy and chemotherapy. Thus, the limitations in response rates may be more a function of the inherent limitations of these existing approaches rather than limitations of gene therapy. Consequently, it is imperative to avoid unrealistic expectations for this emerging approach. Since failure to meet unrealistic expectations in patients with highly advanced disease may discourage further development, reaction to negative trials should be kept in perspective. Indeed, the publication of negative results should be encouraged since this can identify problems in vector and clinical trial design and can point the way to better studies in the future. It would be expected that the response rate to gene-based agents given as single modalities would be as low as those for single-agent chemotherapy. However, gene-based treatments combined with other types of treatment could be very effective. The lack of toxicity of genebased therapies will allow them to be tried with other therapeutics so that additive and synergistic effects can be evaluated.
The fundamental knowledge of the molecular genetics of cancer and the mechanisms underlying carcinogenesis is expanding rapidly. Consequently, the design and testing of therapeutic strategies targeted to the fundamental processes that have gone awry in the cancer cell may allow the development of novel cancer treatment and prevention strategies. Moreover, improvements in vector design that increase the efficiency of expression, that increase the precision of targeting, and that reduce toxicity should also improve response rates. Although much research needs to be done, the possibility of specific gene targeting with a high therapeutic index makes this area of gene therapy a promising one for future investigations. †IL-2 ‫ס‬ interleukin 2; TGF-␤2 ‫ס‬ transforming growth factor-␤2; GM-CSF ‫ס‬ granulocyte-macrophage colony-stimulating factor; NA ‫ס‬ not available; CR ‫ס‬ complete response; PR ‫ס‬ partial response; SD ‫ס‬ stable disease; MR ‫ס‬ minor response; NCI ‫ס‬ National Cancer Institute; PSA ‫ס‬ prostate-specific antigen; CEA ‫ס‬ carcinoembryonic antigen; c-DNA ‫ס‬ complementary DNA; IGF ‫ס‬ insulin-like growth factor; PBLs ‫ס‬ peripheral blood lymphocytes; NATC ‫ס‬ nontransfected autologous tumor cells; TILs ‫ס‬ tumor-infiltrating lymphocytes; TNF ‫ס‬ tumor necrosis factor; LFTS ‫ס‬ liver function tests; CNS ‫ס‬ central nervous system; MDA ‫ס‬ MDA-MB-231 cell line; CML ‫ס‬ chronic myelogenous leukemia; NSCLC ‫ס‬ non-small-cell lung carcinoma; HSV-TK ‫ס‬ herpes simplex virus thymidine kinase; MDR ‫ס‬ multidrug resistance; NEO-R ‫ס‬ neomycin-resistance; and UATC ‫ס‬ untransduced autologous tumor cells.
‡In vivo or in target cell. §All principal investigators were requested to use the following response criteria: a complete response (CR) was defined as the disappearance of all clinical evidence of tumor in the treated area for local treatment or for all lesions for systemic treatment without the appearance of new lesions for a period of at least 4 weeks. Patients evaluable for a less-than-complete response were those having a bidimensionally measurable tumor. Partial response (PR) was defined as a 50% or greater reduction in the sum of the products of the diameters of the measurable disease including the treated lesion for local treatment or all lesions for systemic therapy. A minor response (MR) was defined as a 25% to less than 50% reduction in the sum of the products of the diameters of the measurable lesion. Patients were designated as having progressive disease if they showed a 25% or greater increase in the size of their disease or if they developed unequivocal new lesions during treatment and as having stable disease (SD) if they had any tumor change that did not meet the criteria described above.
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